



NOVO NORDISK OF NORTH AMERICA, INC

FACSIMILE TRANSMITTAL SHEET

TO: Group Art Unit 1626 FROM: Carl M. Farlane - Fishberg
Examiner Robert Gerstl
COMPANY: USPTO, Art Unit 1626 DATE: May 21, 2002
FAX NUMBER: (703) 308-4426 TOTAL NO. OF PAGES INCLUDING COVER: (25)
PHONE NUMBER: (703) 308-4531 SENDER'S PHONE NUMBER: (212) 867-0123
RE: U.S. Serial 09/662,457 SENDER'S FAX NUMBER: (212) 878-9655
Docket #: 5956.200-US
☐ URGENT ☐ FOR REVIEW ☐ PLEASE COMMENT ☐ PLEASE REPLY ☐ PLEASE RECYCLE

NOTES/COMMENTS:

PLEASE NOTE: The information contained in this facsimile message is privileged and confidential, and is intended only for the use of the individual named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, or if any problems occur with the transmission, please contact Babatunde Pedro at 212-878-9683.

405 LEXINGTON AVENUE, SUITE 6400
NEW YORK, NEW YORK 10174

Attorney Docket No.: 5956.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Serial No.: 09/662,457

Group Art Unit: 1626

Filed: September 11, 2000

Examiner: Robert Gerstl

Confirmation No: 9106

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of
Examiner Robert Gerstl, Confirmation No: 9106, fax number (703) 308-4426.

Respectfully submitted,

Date: May 21, 2002



Carol McFarlane-Fishberg
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 5956.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Serial No.: 09/662,457

Group Art Unit: 1626

Filed: September 11, 2000

Examiner: Robert Gerstl

Confirmation No: 9106

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed December 10, 2001.

It is respectfully requested that the time for response to the Office Action dated December 10, 2001 be extended for a period of three (3) months from March 10, 2002 to June 10, 2002. The required fee for the extension is estimated to be \$920.

The fee for claims has been calculated as shown below:

Total: $84 - 74 = 10 \times 18 = \180

Total additional fee for claims required is \$180.

In the event that an extension of time is required, Applicants hereby petition for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Please charge the required extension and claims fees, estimated to be \$1100, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: May 21, 2002

Respectfully submitted,

Cheryl H. Agis

Cheryl H. Agis, Reg. No. 34,086
Outside Counsel for Novo Nordisk
of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 5956.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: 09/662,457

Group Art Unit: 1626

Filed: September 11, 2000

Examiner: Robert Gerstl

Confirmation No: 9106

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents
Washington, DC 20231


Sir:

In response to the Office Action mailed December 10, 2001, please amend the above-captioned application as follows (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

IN THE CLAIMS:

Substitute the following amended claims for the pending claims having the same claim numbers:

1. (Amended) A compound of Formula 1



Formula 1

07/12/2002 RHARMON 00000002 141447 09662457

01 FC:103

180.00 CH